Fred Saad, Andrew J Armstrong, Mototsugu Oya, Karina Vianna, Mustafa Özgüroğlu, Craig Gedye, Gary L Buchschacher, Ji Youl Lee, Urban Emmenegger, Jiri Navratil, Juan Antonio Virizuela, Anibal Salazar, Denis Maillet, Hiroji Uemura, Jeri Kim, Emma Oscroft, Laura Barker, Arnold Degboe, Noel W Clarke
BACKGROUND: The PROpel study (NCT03732820) demonstrated a statistically significant progression-free survival benefit with olaparib plus abiraterone versus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective of homologous recombination repair mutation status. OBJECTIVE: We report additional safety analyses from PROpel to increase clinical understanding of the adverse-event (AE) profiles of olaparib plus abiraterone versus placebo plus abiraterone...
April 5, 2024: European Urology Oncology